The current read
Initial read: commercially encouraging, but the discount is less obvious than the cash balance makes it look. At the September 11 close, Kura's headline enterprise value was approximately $0.50 billion.
- That is about 6x annualized 2Q26 reported revenue—not 1.7x—and even that multiple is a poor shorthand because collaboration revenue is not recurring product economics. The launch is real: KOMZIFTI produced $9.1 million in 2Q26 revenue, approximately 115 new starts and more than 250 total prescriptions.
- Kura says it won a majority of new R/R NPM1-mutated AML starts within the menin class. Once-daily dosing and the absence of Revuforj's boxed QTc/Torsades warning are credible commercial advantages, although KOMZIFTI still requires ECG, electrolyte and drug-interaction management.
- The economics are shared: Kura retains 50% of U.S. profit, funds the agreed global development plan through 2028 and currently addresses adults with R/R NPM1-mutated AML only. Syndax retains broader KMT2A and pediatric labels, so the valuation gap is not just a market-share judgment.
- The value step-up is also deferred. KOMET-007 produced 96% and 90% CRc rates in newly diagnosed NPM1-mutated and KMT2A-rearranged AML, respectively, with 94% 12-month survival in NPM1.
- Those results are impressive, but uncontrolled and layered onto active chemotherapy. The approximately 1,300-patient KOMET-017 program is the test; first pivotal topline is guided to 2028.
- Darlifarnib is legitimate optionality, not current value support. Its randomized cabozantinib comparison in clear-cell RCC is the first cleaner contribution test and is due in 2H27.
- The old tipifarnib/HNSCC thesis should stay out of base value unless Kura commits to a new darlifarnib combination program.